The Effect of Proton Pump Inhibitors on Bone Formation in a Rat Spinal Arthrodesis Model

被引:5
作者
Sonn, Kevin A. [1 ]
Wallace, Stephen J. [1 ]
Yuan, Feng Ning F. [1 ]
Schneider, Andrew D. [2 ]
Hsu, Erin L. [2 ]
Havey, Robert M. [3 ]
Patwardhan, Avinash G. [3 ]
Callaci, John J. [1 ]
机构
[1] Loyola Univ Med Ctr, Maywood, IL 60153 USA
[2] Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA
[3] Edward Hines Jr VA Hosp, Hines, IL USA
关键词
arthrodesis; bone biology; bone formation; non-union; Pantoprazole; proton pump inhibitor; pseudarthrosis; risk factor; rodent; spine fusion; FUSION; OMEPRAZOLE; THERAPY; SURGERY; PANTOPRAZOLE; EXPRESSION; FRACTURE; RHBMP-2; SMOKING; IMPACT;
D O I
10.1097/BRS.0000000000002987
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Study Design. Rat posterolateral arthrodesis model. Objective. Quantify the impact of administration of a proton pump inhibitor on spine fusion. Summary of Background Data. Proton pump inhibitors (PPIs) are widely used for gastrointestinal disorders and for ulcer prophylaxis in patients taking non-steroidal anti-inflammatory drugs. PPIs cause chronic acid suppression which has been found to result in decreased bone mineral density, increased fracture risk, and impaired fracture healing. Despite advances in surgical techniques, pseudarthrosis still occurs in up to 24% of patients requiring revision surgery following spinal fusion procedures. Thus, there are likely many unidentified risk factors. While PPIs have been hypothesized to impact fracture healing, no study has evaluated their effect on spine arthrodesis rates. Methods. Thirty-eight female rats underwent posterolateral lumbar spinal fusion. Rats were divided into two groups: normal saline control and pantroprazole, which was administered by daily intraperitoneal injections. At 8 weeks postoperative spines were evaluated with manual palpation, microCT, histologic analysis, and biomechanical testing. Results. Fusion rates of the control group and PPI group were not significantly different (100% vs. 94%). Average fusion scores were significantly lower in the pantoprazole group. New bone formation identified on microCT imaging of bilaterally fused specimens demonstrated a lower average volume of newly generated bone in the PPI group, but this difference was not significant. Biomechanical testing demonstrated no significant difference in strength or stiffness of the fusion mass between the groups. Conclusion. This study demonstrates that administration of PPIs does not inhibit fusion rates, bone formation, or affect biomechanical integrity of fusion. However, lower fusion scores in the PPI group suggest that a negative impact may still exist. Future studies will explore growth factor and protein expression in the fusion masses as well as utilize higher doses of PPI to fully discern their effect on spine fusion.
引用
收藏
页码:E815 / E822
页数:8
相关论文
共 50 条
  • [31] Effect of proton pump inhibitors on mortality of cirrhotic patients with pneumonia
    Hung, Tsung-Hsing
    Tseng, Chih-Wei
    Tsai, Chih-Chun
    Lee, Hsing-Feng
    [J]. PLOS ONE, 2019, 14 (04):
  • [32] Effect of proton pump inhibitors on voriconazole concentrations in Chinese patients with malignant hematological diseases
    Huang, Qi
    Liu, Qiong
    Yin, Tao
    Hu, Lin
    Ding, Hanjun
    Liu, Shao
    Jiang, Yueping
    [J]. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2020, 76 (06) : 833 - 842
  • [33] The effect of cannabinoids on single-level lumbar arthrodesis outcomes in a rat model
    Fogel, Harold
    Yeritsyan, Diana
    Momenzadeh, Kaveh
    Kheir, Nadim
    Yeung, Caleb M.
    Abbasian, Mohammadreza
    Lozano, Edith Martinez
    Nazarian, Rosalynn M.
    Nazarian, Ara
    [J]. SPINE JOURNAL, 2024, 24 (09) : 1759 - 1772
  • [34] Correlation of Bone Mineral Density Scores and Proton Pump Inhibitors Use in the Elderly
    Amoako, Adae O.
    Jafilan, Lena
    Nasiri, Papia
    Pujalte, George G. A.
    [J]. CURRENT RHEUMATOLOGY REVIEWS, 2016, 12 (02) : 162 - 166
  • [35] Characterizing the Host Response to rhBMP-2 in a Rat Spinal Arthrodesis Model
    Hsu, Wellington K.
    Polavarapu, Mahesh
    Riaz, Rehan
    Larson, Andrew C.
    Diegmueller, Jared J.
    Ghodasra, Jason H.
    Hsu, Erin L.
    [J]. SPINE, 2013, 38 (12) : E691 - E698
  • [36] Proton Pump Inhibitors and Bone Health: An Update Narrative Review
    Lespessailles, Eric
    Toumi, Hechmi
    [J]. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2022, 23 (18)
  • [37] The relationship among proton pump inhibitors, bone disease and fracture
    Targownik, Laura E.
    Leslie, William D.
    [J]. EXPERT OPINION ON DRUG SAFETY, 2011, 10 (06) : 901 - 912
  • [39] The effect of proton pump inhibitors on fracture risk: report from the Canadian Multicenter Osteoporosis Study
    Fraser, L-A.
    Leslie, W. D.
    Targownik, L. E.
    Papaioannou, A.
    Adachi, J. D.
    [J]. OSTEOPOROSIS INTERNATIONAL, 2013, 24 (04) : 1161 - 1168
  • [40] Effect of long-term proton pump inhibitors on phosphocalcium metabolism and bone mineral density
    Smaoui, Hend
    Chtourou, Lassaad
    Jallouli, Dana
    Jemaa, Samar Ben
    Karaa, Iheb
    Boudabbous, Mouna
    Moalla, Manel
    Gdoura, Hela
    Mnif, Leila
    Amouri, Ali
    Akrout, Rim
    Ayadi, Fatma
    Baklouti, Sofien
    Tahri, Nabil
    [J]. FUTURE SCIENCE OA, 2024, 10 (01):